GENinCode Plc (LON:GENI – Get Free Report) hit a new 52-week low on Wednesday . The stock traded as low as GBX 0.80 and last traded at GBX 0.95, with a volume of 14639052 shares. The stock had previously closed at GBX 0.88.
GENinCode Price Performance
The firm has a market cap of £6.29 million, a PE ratio of -0.37 and a beta of 0.59. The company has a quick ratio of 15.88, a current ratio of 0.93 and a debt-to-equity ratio of 117.74. The stock has a 50 day moving average price of GBX 1.10 and a two-hundred day moving average price of GBX 1.47.
GENinCode (LON:GENI – Get Free Report) last posted its quarterly earnings data on Monday, June 8th. The company reported GBX (2.08) earnings per share (EPS) for the quarter. The company had revenue of GBX 308 million for the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. As a group, equities analysts expect that GENinCode Plc will post -7.1299999 earnings per share for the current year.
About GENinCode
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.
Featured Articles
- Five stocks we like better than GENinCode
- Buyback Capacity Is Rising Across 3 Soaring and Sinking Stocks
- How to Invest in the Biggest European Defense Surge in Decades
- The Netflix-Lionsgate Rumor Exposed a Bigger Shift in Media M&A
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
Receive News & Ratings for GENinCode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENinCode and related companies with MarketBeat.com's FREE daily email newsletter.
